CD274 and neoplasm: Clinical trials evaluating [89Zr]Zr-DFO-nivolumab (targeting PD-1) are currently ongoing but in an initial study of [89Zr]Zr-DFO-nivolumab and [18F]F-anti-PD-L1 adnectin whole body PET/ CT scans correlated with tumor PD-1 and PD-L1 expression as assessed by IHC [115].